REFERENCES
1. Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96.
2. Reiss AB, Glass DS, Voloshyna I, Glass AD, Kasselman LJ, De Leon J. Obesity and atherosclerosis: the exosome link. VP 2020;4:19.
3. Bour S, Caspar-Bauguil S, Iffiú-Soltész Z, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 deficiency reduces leukocyte infiltration into adipose tissue and favors fat deposition. Am J Pathol 2009;174:1075-83.
4. Jargaud V, Bour S, Tercé F, et al. Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity. J Physiol Biochem 2020; doi: 10.1007/s13105-020-00756-y.
5. Stolen CM, Marttila-Ichihara F, Koskinen K, et al. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 2005;22:105-15.
6. de Carvalho L, Bligt-Lindén E, Ramaiah A, Johnson MS, Salminen TA. Evolution and functional classification of mammalian copper amine oxidases. Mol Phylogenet Evol 2019;139:106571.
7. Salmi M, Jalkanen S. Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation. Antioxid Redox Signal 2019;30:314-32.
8. Boomsma F, Bhaggoe UM, van der Houwen AM, van den Meiracker AH. Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2003;1647:48-54.
9. Carpéné C, Boulet N, Chaplin A, Mercader J. . Past, Present and Future Anti-Obesity Effects of Flavin-Containing and/or Copper-Containing Amine Oxidase Inhibitors. Medicines (Basel) 2019;6:9.
10. Dunkel P, Balogh B, Meleddu R, Maccioni E, Gyires K, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat 2011;21:1453-71.
11. Silvola JM, Virtanen H, Siitonen R, Hellberg S, Liljenback H, et al. Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques. Sci Rep 2016;6:35089.
12. Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, et al. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood) 2009;234:354-60.
13. Souto RP, Vallega G, Wharton J, Vinten J, Tranum-Jensen J, et al. Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signaling. J Biol Chem 2003;278:18321-9.
14. Yang H, Ralle M, Wolfgang MJ, Dhawan N, Burkhead JL, et al. Copper-dependent amino oxidase 3 governs selection of metabolic fuels in adipocytes. PLoS Biol 2018;16:e2006519.
15. Noonan T, Lukas S, Peet GW, Pelletier J, Panzenbeck M, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol 2013;2:172-85.
16. Iffiu-Soltesz Z, Wanecq E, Lomba A, Portillo MP, Pellati F, et al. Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res 2010;61:355-63.
17. Morin N, Visentin V, Calise D, Marti L, Zorzano A, et al. Tyramine stimulates glucose uptake in insulin-sensitive tissues in vitro and in vivo via its oxidation by amine oxidases. J Pharmacol Exp Ther 2002;303:1238-47.
18. Leroux M, Lemery T, Boulet N, Briot A, Zakaroff A, et al. Effects of the amino acid derivatives, β-hydroxy-β-methylbutyrate, taurine, and N-methyltyramine, on triacylglycerol breakdown in fat cells. J Physiol Biochem 2019;75:263-73.
19. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-7.
20. Vieu C, Jaspard B, Barbaras R, Manent J, Chap H, et al. Identification and quantification of diacylglycerols in HDL and accessibility to lipase. J Lipid Res 1996;37:1153-61.
21. Wu JT, Tu MC, Zhung P. Advanced glycation end product (AGE): characterization of the products from the reaction between D-glucose and serum albumin. J Clin Lab Anal 1996;10:21-34.
22. Szökő E, Tábi T, Halász A, Pálfi M, Magyar K. High sensitivity analysis of nitrite and nitrate in biological samples by capillary zone electrophoresis with transient isotachophoretic sample stacking. J Chromatogr ;1051:177-83.
23. Les F, Deleruyelle S, Cassagnes LE, Boutin JA, Balogh B, et al. Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. Chem Biol Interact 2016;258:115-25.
24. Carpéné C, Desquesnes A, Gomez-Ruiz A, Iffiu-Soltesz Z, Le Gonidec S, et al. Long-term activation of semicarbazide-sensitive amine oxidase lowers circulating levels of uric acid in diabetic conditions. Physiol Res 2012;61:251-7.
25. Garcia-Vicente S, Yraola F, Marti L, Gonzalez-Munoz E, Garcia-Barrado MJ, et al. Oral insulin-mimetic compounds that act independently of insulin. Diabetes 2007;56:486-93.
26. Yraola F, Garcia-Vicente S, Marti L, Albericio F, Zorzano A, et al. Understanding the mechanism of action of the novel SSAO substrate (C7NH10)6(V10O28).2H2O, a prodrug of peroxovanadate insulin mimetics. Chem Biol Drug Des 2007;69:423-8.
27. Stolen CM, Yegutkin GG, Kurkijarvi R, Bono P, Alitalo K, et al. Origins of serum semicarbazide-sensitive amine oxidase. Circ Res 2004;95:50-7.
28. Marttila-Ichihara F, Smith DJ, Stolen C, Yegutkin GG, Elima K, et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 2006;54:2852-62.
29. Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest 2015;125:501-20.
30. Mercier N, Osborne-Pellegrin M, El Hadri K, Kakou A, Labat C, et al. . Carotid arterial stiffness, elastic fibre network and vasoreactivity in semicarbazide-sensitive amine-oxidase null mouse. Cardiovasc Res 2006;72:349-57.
31. Bour S, Prévot D, Guigne C, Stolen C, Jalkanen S, et al. Semicarbazide-sensitive amine oxidase substrates fail to induce insulin-like effects in fat cells from AOC3 knockout mice. J Neural Transm (Vienna) 2007;114:829-33.
32. Gres S, Bour S, Valet P, Carpene C. Benzylamine antihyperglycemic effect is abolished by AOC3 gene invalidation in mice but not rescued by semicarbazide-sensitive amine oxidase expression under the control of aP2 promoter. J Physiol Biochem 2012;68:651-62.
33. Toivonen R, Vanhatalo S, Hollmén M, Munukka E, Keskitalo A, et al. Vascular Adhesion Protein 1 mediates gut microbial flagellin-induced inflammation, leukocyte infiltration, and hepatic steatosis. Sci 2019;1:65.
34. Champy MF, Selloum M, Piard L, Zeitler V, Caradec C, et al. Mouse functional genomics requires standardization of mouse handling and housing conditions. Mamm Genome 2004;15:768-83.
35. Boulet N, Estève D, Bouloumié A, Galitzky J. Cellular heterogeneity in superficial and deep subcutaneous adipose tissues in overweight patients. J Physiol Biochem 2013;69:575-83.
36. Sablé R, Sicart R, Berry E. Steroid pattern of bile and feces in response to a fruit-enriched diet in hypercholesterolemic hamsters. Ann Nutr Metab 1990;34:303-10.
37. Kobayashi T, Kamata K. Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. Atherosclerosis 2001;155:313-20.
38. Mercier N, Pawelzik SC, Pirault J, Carracedo M, Persson O, et al. Semicarbazide-Sensitive Amine Oxidase Increases in Calcific Aortic Valve Stenosis and Contributes to Valvular Interstitial Cell Calcification. Oxid Med Cell Longev 2020;2020:5197376.
39. Dong ZM, Gutierrez-Ramos JC, Coxon A, Mayadas TN, Wagner DD. A new class of obesity genes encodes leukocyte adhesion receptors. Proc Natl Acad Sci U S A 1997;94:7526-30.
40. Liu X, Huh JY, Gong H, Chamberland JP, Brinkoetter MT, et al. Lack of mature lymphocytes results in obese but metabolically healthy mice when fed a high-fat diet.
41. Shepherd EL, Karim S, Newsome PN, Lalor PF. Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo. World J Hepatol 2020;12:931-48.
42. Tilg H, Burcelin R, Tremaroli V. Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis? Gut 2020;69:1373-4.
43. Lyles GA. Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. Prog Brain Res 1995;106:293-303.
44. Li C, Wang Z, Li X, Chen J. Effects of semicarbazide-sensitive amine oxidase inhibitors on morphology of aorta and kidney in diabetic rats. BMC Endocr Disord 2019;19:59.
45. Mercier N, El Hadri K, Osborne-Pellegrin M, Nehme J, Perret C, et al. Modifications of arterial phenotype in response to amine oxidase inhibition by semicarbazide. Hypertension 2007;50:234-41.
46. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 2007;71:266-71.
47. Cherezova A, Tomilin V, Buncha V, Zaika O, Ortiz PA, et al. Urinary concentrating defect in mice lacking Epac1 or Epac2. Faseb j 2019;33:2156-70.
48. Papukashvili D, Rcheulishvili N, Deng Y. Beneficial impact of Semicarbazide-Sensitive Amine Oxidase inhibition on the potential cytotoxicity of creatine supplementation in type 2 diabetes mellitus. Molecules 2020;25:2029.
49. Carroll JF, King JW, Cohen JS. Hydralazine treatment alters body composition in the rabbit model of obesity. Acta Physiol Scand 2004;181:183-91.
50. Yu PH, Wang M, Fan H, Deng Y, Gubisne-Haberle D. Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KKAy mice. Am J Physiol Endocrinol Metab 2004; 286:E634-41.
51. Mercader J, Iffiu-Soltesz Z, Bour S, Carpéné C. Oral administration of semicarbazide limits weight gain together with inhibition of fat deposition and of primary amine oxidase activity in adipose tissue. J Obes 2011;2011:475786.
52. Carpéné C, Mercader J, Le Gonidec S, Schaak S, Mialet-Perez J, et al. Body fat reduction without cardiovascular changes in mice after oral treatment by the MAO inhibitor phenelzine. Br J Pharmacol 2018;175:2428-40.
53. Mercader J, Sabater A, Le Gonidec S, Decaunes P, Chaplin A, et al. Oral phenelzine treatment mitigates metabolic disturbances in mice fed a high-fat diet. J Pharmacol Exp Ther 2019; 371:555-66.
54. Papukashvili D, Rcheulishvili N, Deng Y. Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO. Nutrients 2020;12:184.
55. Wang SH, Yu TY, Tsai FC, Weston CJ, Lin MS, et al. Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in apolipoprotein E-deficient mice. Transl Res 2018; 197:12-31.
56. Wang SH, Yu TY, Hung CS, Yang CY, Lin MS, et al. Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in cholesterol-fed New Zealand white rabbits. Sci Rep 2018;8:9249.
57. Zhang M, Liu L, Zhi F, Niu P, Yang M, et al. Inactivation of semicarbazide-sensitive amine oxidase induces the phenotypic switch of smooth muscle cells and aggravates the development of atherosclerotic lesions. Atherosclerosis 2016;249:76-82.
58. Yu PH, Wang M, Deng YL, Fan H, Shira-Bock L. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet. Diabetologia 2002;45:1255-62.
59. Aalto K, Maksimow M, Juonala M, Viikari J, Jula A, et al. Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations. Arterioscler Thromb Vasc Biol 2012;32:523-32.
